DBV Technologies | DBVT - Current Liabilities



DBV Technologies reported $49.42M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Amarin USD 162.41M 17.54M Mar/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
DBV Technologies USD 49.42M 9.04M Jun/2025
Halozyme Therapeutics USD 134.28M 16.1M Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
Insmed USD 311.68M 72.45M Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
PTC Therapeutics USD 627.81M 32.42M Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
United Therapeutics USD 527.1M 194.4M Jun/2025